HOWARD MOON
HOWARD MOON is named as a lobbyist in 1 lobbying report we hold, filed by 1 registrant for 1 client.
Earlier government jobs, as reported
A lobbying report lists each lobbyist's covered positions: jobs in Congress or the executive branch that the law asks a lobbyist to disclose. Each line is copied as a report states it.
No report we hold lists a covered position for HOWARD MOON.
Registrants and clients
- AMGEN, INC. · 1 report
Clients: AMGEN INC.
Bills named where this lobbyist is listed, and how the House and the Senate voted
28 bills named in these reports. 2 of them became law, and our record holds how the House and the Senate voted on them. A lobbying report names the houses of Congress and the agencies the lobbyists contacted. It does not say which members or staff they met.
| Bill | Status | How the House and the Senate voted |
|---|---|---|
| H.R. 1An act to provide for reconciliation pursuant to title II of H. Con. Res. 14. | Became law | Public Law 119-21House 218–214 · Senate 50–50 |
| S. 2Secure America Act | Became law | Public Law 119-98House 214–212 · Senate 52–47 |
| H.Con.Res. 14Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. | Passed both chambers | No recorded vote in our record |
| H.R. 1492To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. | Introduced | No recorded vote in our record |
| H.R. 1672Maintaining Investments in New Innovation Act | Introduced | No recorded vote in our record |
| H.R. 4299Protecting Patient Access to Cancer and Complex Therapies Act | Introduced | No recorded vote in our record |
| H.R. 4317PBM Reform Act of 2025 | Introduced | No recorded vote in our record |
| H.R. 5256340B ACCESS Act | Introduced | No recorded vote in our record |
| H.R. 5526Biosimilar Red Tape Elimination Act | Introduced | No recorded vote in our record |
| H.R. 6166Lowering Drug Costs for American Families Act | Introduced | No recorded vote in our record |
| H.R. 6624Biological Intellectual Property Protection Act of 2025 | Introduced | No recorded vote in our record |
| H.R. 7391Community Health Center Drug Pricing Protection Act | Introduced | No recorded vote in our record |
| H.R. 7837Most Favored Patient Act of 2026 | Introduced | No recorded vote in our record |
| H.R. 8143Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026. | Introduced | No recorded vote in our record |
| H.R. 8646Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 | Passed the House | No recorded vote in our record |
| H.R. 8800National Defense Authorization Act for Fiscal Year 2027 | Passed the House | No recorded vote in our record |
| H.R. 9102BINSA Act | Introduced | No recorded vote in our record |
| S. 1414Expedited Access to Biosimilars Act | Reported by committee | No recorded vote in our record |
| S. 1954Biosimilar Red Tape Elimination Act | Reported by committee | No recorded vote in our record |
| S. 2355Patients Deserve Price Tags Act | Reported by committee | No recorded vote in our record |
| S. 3014Ensuring Timely Access to Generics Act of 2025 | Introduced | No recorded vote in our record |
| S. 3019No Big Blockbuster Bailouts Act | Introduced | No recorded vote in our record |
| S. 3345PBM Price Transparency and Accountability Act | Introduced | No recorded vote in our record |
| S. 3349PBM Disclosure Act | Introduced | No recorded vote in our record |
| S. 3452Biological Intellectual Property Protection Act of 2025 | Introduced | No recorded vote in our record |
| S. 3510Biosimilar Inspection Modernization Act of 2025 | Introduced | No recorded vote in our record |
| S. 3788CLEAR LABELS Act | Reported by committee | No recorded vote in our record |
| S. 4323Ensuring Access to Lower-Cost Medicines for Seniors Act | Introduced | No recorded vote in our record |
Issues named: Health Issues (1), Medicare/Medicaid (1), Tariff (miscellaneous tariff bills) (1).
Every report
| Client | Registrant | Kind, as filed | Posted | Report |
|---|---|---|---|---|
| AMGEN INCHealth Issues, Medicare/Medicaid, Tariff (miscellaneous tariff bills) | AMGEN, INC. | 2nd Quarter - Report | The report on LDA.gov |
Campaign gifts this lobbyist reported
Lobbyists and registrants report their political contributions twice a year (form LD-203). We hold these reports only for contributions to the campaign committees of members who sponsored or cosponsored a bill named in a lobbying report. Any other contribution: Not checked yet.
| Member | Paid to, as reported | Amount | Date | Report |
|---|---|---|---|---|
| Eugene Simon Vindman DDemocrat | VINDMAN FOR CONGRESSFrom SELF | $500 | The report on LDA.gov |
Where this comes from
Lobbying Disclosure Act reports (LD-2), LDA.gov. We save our own copy of each page of LDA.gov's list of reports before we read it. These pages were built from our copies on .
2026-Q2: every page of LDA.gov's list saved and read.
A lobbying report states the registrant's income from the client (a lobbying firm) or its own lobbying expenses (an organization lobbying for itself), for the whole quarter and every issue together. A report of less than $5,000, or of no lobbying activity, states no figure. It is not the amount spent on one bill.
Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.